Venture Market News for October 29, 2018
- Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the Company filed an investigational new drug application (IND) with the U.S. Food & Drug Administration (FDA) to initiate A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer. The trial, sponsored by Generex wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) and conducted in conjunction with research partners Merck and the NSABP Foundation, Inc. (NSABP), is scheduled to initiate sites in the fourth quarter and to begin enrolling patients in the first quarter of 2019.
- New STAIRWAY study data shows potential for extended durability with Roche’s faricimab in neovascular age-related macular degeneration (nAMD)
October 29, 2018–OTC Disclosure & News Service–Basel, Switzerland —
This release includes additional documents. Select the link(s) below to view.
inv-update-2018-10-29-New STAIRWAY study data shows potential for extended durability with Roche’s faricimab in neovascular age-related macular degeneration (nAMD).pdf
- Cannmart Signs Supply Agreement With Rocky Mountain Marijuana Inc. Including a 20% First Right of Refusal
VANCOUVER, Oct. 29, 2018 /CNW/ – Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company’s wholly-owned subsidiary, Cannmart Inc. (“Cannmart”), has signed a medical cannabis supply agreement (the “Agreement”) with RMMI Corp.’s (CSE: RMMI) wholly-owned subsidiary, Rocky Mountain Marijuana Inc. (“RMMI”), whereby Cannmart will purchase medical cannabis from RMMI to offer in its online platform. Subject to the terms of the Agreement, Cannmart will have the right of first refusal (“ROFR”) on 20% of RMMI’s gross production.
- CBB Bancorp, Inc. Reports ROA of 1.51% and ROE of 13.77% for the Third Quarter of 2018
CBB Bancorp, Inc. (“CBB” or the “Company”) (OTCQB: CBBI), the holding company of Commonwealth Business Bank (the “Bank”), today announced net income for the third quarter of 2018 of $4.4 million, or $0.42 per diluted share, an increase of 17.9% compared to $3.7 million or $0.36 per diluted share in the same period last year. Earnings per share and per share data has been adjusted to reflect the impact of a 10% stock dividend that was declared on October 2, 2018.
Connect with 24/7 Market News on social media:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.
24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. 24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
For further information on 24/7 Market News, please go to www.247marketnews.com
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements
24/7 Market News